Library

Advocacy for mental health / Michelle Funk ; Benedetto Saraceno ; Alberto Minoletti ; World Health Organization / Geneva [Switzerland] : World Health Organisation (WHO) (2003)

Advocacy for mental health [printed text] / Michelle Funk ; Benedetto Saraceno ; Alberto Minoletti ; World Health Organization . - Geneva [Switzerland] : World Health Organisation (WHO), 2003 . - xiii, 54 p. : ill. ; 30 cm. - (Mental health policy and service guidance package) . ISBN : 978-92-4-154590-7 The Mental health policy and service guidance package was produced under the direction of Michelle Funk and supervised by Benedetto Saraceno. Alberto Minoletti prepared this module--P. iii. Languages : English (eng) Descriptors: Classification WM 30 Administrative psychiatry Indexation Consumer Advocacy ; Guidelines as Topic ; Mental Health ; Mental Health Services ; Mentally Ill Persons ; Patient Advocacy ; Public Policy Class number: 362.2 Abstract: Advocacy is an important means of raising awareness on mental health issues and ensuring that mental health is on the national agenda of governments. Advocacy can lead to improvements in policy, legislation and service development Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1036

Hold

Place a hold on this item

Copies(1)

Barcode	Call number	Media type	Location	Section	Status
10273-01573	WM 30/WHO	Guideline	KCE	Library (10.124)	Available

Belgian guidelines for economic evaluations / Nancy Thiry in International Journal of Technology Assessment in Health Care, 30(2014)06 ([12/01/2014])  

[article] Belgian guidelines for economic evaluations : 2nd edition [printed text] / Nancy Thiry, Author ; Mattias Neyt , Author ; Stefaan Van de Sande , Author ; Irina Cleemput , Author . - 2014 . - 601-607. Languages : English (eng) in International Journal of Technology Assessment in Health Care > 30(2014)06 [12/01/2014] . - 601-607 Descriptors: Classification QV 736 Drug industry. Economics of pharmacy. Advertising Indexation 2011-44 ; Belgium ; Economics, Pharmaceutical ; Guidelines as Topic ; Journal Article ; Peer Review ; R183 Abstract: OBJECTIVES: The aim of this study was to present the updated methodological guidelines for economic evaluations of healthcare interventions (drugs, medical devices, and other interventions) in Belgium. METHODS: The update of the guidelines was performed by three Belgian health economists following feedback from users of the former guidelines and personal experience. The updated guidelines were discussed with a multidisciplinary team consisting of other health economists, assessors of reimbursement request files, representatives of Belgian databases and representatives of the drugs and medical devices industry. The final document was validated by three external validators that were not involved in the previous discussions. RESULTS: The guidelines give methodological guidance for the following components of an economic evaluation: literature review, perspective of the evaluation, definition of the target population, choice of the comparator, analytic technique and study design, calculation of costs, valuation of outcomes, definition of the time horizon, modeling, handling uncertainty and discounting. We present a reference case that can be considered as the minimal requirement for Belgian economic evaluations of health interventions. CONCLUSIONS: These guidelines will improve the methodological quality, transparency and uniformity of the economic evaluations performed in Belgium. The guidelines will also provide support to the researchers and assessors performing or evaluating economic evaluations. Link for e-copy: http://dx.doi.org/10.1017/S0266462314000725 Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3655 [article]

Belgian guidelines for economic evaluations and budget impact analyses / Irina Cleemput / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)  

Belgian guidelines for economic evaluations and budget impact analyses : second edition [printed text] / Irina Cleemput , Author ; Mattias Neyt , Author ; Stefaan Van de Sande , Author ; Nancy Thiry, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2012 . - VII, 76 p. : ill. ; A4. - (KCE Reports. Health Technology Assessment (HTA); 183C) . ISSN : D/2012/10.273/54 : € 0,00 Study n° 2011-44 HTA Pharma-Eco Evaluation Update Languages : English (eng) Descriptors: Classification QV 736 Drug industry. Economics of pharmacy. Advertising Indexation 2011-44 ; Economics, Pharmaceutical ; Guidelines as Topic ; R183 Contents note: SCIENTIFIC REPORT 8 -- 1 BACKGROUND 8 -- 2 OBJECTIVES 10 -- 3 METHODS10 -- 4 OVERVIEW OF THE BELGIAN GUIDELINES AND GENERAL REMARKS 12 -- 4.1 OVERVIEW OF THE BELGIAN GUIDELINES 12 -- 4.2 GENERAL REMARKS 13 -- 5 GUIDELINES FOR HEALTH ECONOMIC EVALUATIONS 15 -- 5.1 GUIDELINE 1: LITERATURE REVIEW 15 -- 5.2 GUIDELINE 2: PERSPECTIVE OF THE EVALUATION 17 -- 5.3 GUIDELINE 3: TARGET POPULATION 18 -- 5.4 GUIDELINE 4: COMPARATORS 19 -- 5.5 GUIDELINE 5: ANALYTIC TECHNIQUE 21 -- 5.5.1 Cost-effectiveness analysis 21 -- 5.5.2 Cost-utility analysis 22 -- 5.5.3 Cost-minimisation analysis 22 -- 5.5.4 Cost-benefit analysis 23 -- 5.6 GUIDELINE 6: STUDY DESIGN 23 -- 5.6.1 Trial-based economic evaluations 23 -- 5.6.2 Modelling 24 -- 5.7 GUIDELINE 7: CALCULATION OF COSTS 25 -- 5.7.1 Cost categories 25 -- 5.7.2 Measurement of resource use 26 -- 5.7.3 Valuation of resource use 26 -- 5.8 GUIDELINE 8: ESTIMATION AND VALUATION OF OUTCOMES 36 -- 5.8.1 Effectiveness evaluation in cost-effectiveness analysis 37 -- 5.8.2 Utility assessment in cost-utility analysis 37 -- 5.9 GUIDELINE 9: TIME HORIZON 39 -- 5.10 GUIDELINE 10: MODELLING 39 -- 5.10.1 Need for modelling 39 -- 5.10.2 Choice of the model design 40 -- 5.10.3 Precision of model structure and hypotheses 40 -- 5.10.4 Calibration, face validity and cross-validation of a model 41 -- 5.11 GUIDELINE 11: HANDLING UNCERTAINTY AND TESTING THE ROBUSTNESS OF THE RESULTS 42 -- 5.12 GUIDELINE 12: DISCOUNT RATE 43 -- 6 GUIDELINES FOR BUDGET IMPACT ANALYSES 44 -- 6.1 SIMILARITIES AND DIFFERENCES BETWEEN ECONOMIC EVALUATIONS AND BUDGET IMPACT -- ANALYSES 44 -- 6.2 GUIDELINE 13: PERSPECTIVE 45 -- 6.3 GUIDELINE 14: TARGET POPULATION 45 -- 6.4 GUIDELINE 15: COMPARATORS 46 -- 6.5 GUIDELINE 16: COSTS AND OUTCOMES 47 -- 6.6 GUIDELINE 17: TIME HORIZON 48 -- 6.7 GUIDELINE 18: MODELLING 48 -- 6.8 GUIDELINE 19: HANDLING UNCERTAINTY 49 -- 6.9 GUIDELINE 20: DISCOUNT RATE 49 -- 6.10 GUIDELINE 21: PRESENTING RESULTS 49 -- 7 DISCUSSION 50 -- 8 POLICY RECOMMENDATIONS 51 -- 9 REPORTING GUIDELINES 53 -- 9.1 EXECUTIVE SUMMARY 53 -- 9.2 INTRODUCTION 53 -- 9.3 OBJECTIVES 53 -- 9.4 LITERATURE REVIEW 53 -- 9.4.1 Clinical literature review 53 -- 9.4.2 Economic literature review 54 -- 9.5 BASIC ELEMENTS OF THE ECONOMIC EVALUATION 54 -- 9.5.1 Analytic technique 54 -- 9.5.2 Study design 54 -- 9.5.3 Methods used for valuation of costs 54 -- 9.5.4 Methods used for outcome assessment 54 -- 9.5.5 Method of analysis of the data 54 -- 9.5.6 Time horizon and discount rate54 -- 9.5.7 Sensitivity analysis 54 -- 9.6 RESEARCH METHODS 54 -- 9.6.1 Identification, measurement and valuation of costs 54 -- 9.6.2 Identification, measurement and valuation of health-related outcomes 55 -- 9.7 RESULTS 55 -- 9.7.1 Basic results 55 -- 9.7.2 Uncertainty analysis 55 -- 9.8 DISCUSSION 55 -- 9.9 CONCLUSION 55 -- 9.10 TRANSPARENCY OF FINANCIAL SUPPORT 55 -- 9.11 REFERENCES 56 -- 9.12 ADDENDA 56 -- 10 PRESENTATION OF A MODEL 56 -- 10.1 DATA 56 -- 10.2 RESULTS 56 -- 10.2.1 Reference case analysis 56 -- 10.2.2 Uncertainty analysis 56 -- 11 METHODOLOGICAL REFERENCES BY TOPIC 57 -- 11.1 COUNTRY-SPECIFIC GUIDELINES 57 -- 11.2 METHODS FOR ECONOMIC EVALUATIONS 57 -- 11.3 LITERATURE REVIEW 58 -- 11.4 STUDY DESIGN 58 -- 11.4.1 Trial-based economic evaluations 58 -- 11.4.2 Modelling 58 -- 11.5 CALCULATION OF COSTS 58 -- 11.5.1 Measurement of resource use 58 -- 11.5.2 Valuation of resource use 58 -- 11.6 HANDLING UNCERTAINTY 58 -- 11.6.1 Overview 58 -- 11.6.2 Confidence interval around the ICER 59 -- 11.7 INDIRECT COMPARISONS 59 -- 11.8 DISCOUNTING 59 -- 11.9 BUDGET IMPACT ANALYSES 59 -- APPENDICES 60 -- APPENDIX 1. CLASSIFICATION OF ECONOMIC STUDIES 60 -- APPENDIX 2. CHECKLIST FOR ASSESSING ECONOMIC EVALUATIONS 61 -- APPENDIX 3. DATA EXTRACTION SHEET FOR ECONOMIC EVALUATIONS 61 -- APPENDIX 4. TECHNICAL NOTES 62 -- APPENDIX 4.1. ASSESSMENT OF EXTERNAL VALIDITY 62 -- APPENDIX 4.2. OUTCOME VALUATION 63 -- APPENDIX 4.3. USE OF EXPERT PANELS 64 -- APPENDIX 4.4. HOSPITAL PER DIEM PRICES 64 -- APPENDIX 4.5. INDIRECT COMPARISONS 66 -- APPENDIX 5. THE COST-EFFECTIVENESS PLANE, COST-EFFECTIVENESS ACCEPTABILITY CURVE, AND EFFICIENCY FRONTIER 67 -- APPENDIX 6. LIST OF BELGIAN DATABASES FOR THE MEASUREMENT AND VALUATION OF RESOURCE USE 70 -- APPENDIX 7. FLEMISH EQ-5D INDEX VALUES 73 -- REFERENCES 74 Link for e-copy: https://doi.org/10.57598/R183C Format of e-copy: pdf (797 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3020

Hold

Place a hold on this item

Copies(1)

Barcode	Call number	Media type	Location	Section	Status
10273-02535	QV 736 / CLE	Report	KCE	Library (10.124)	Due for return by 12/31/2020

Readers who borrowed this document also borrowed:

How's Life?
The Hastings Center Guidelines for Decisions on Life-Sustaining Treatment and Care Near the End of Life	Berlinger, Nancy
Economics of health care financing	Donaldson, Cam
Carol Gilligan et l'éthique du care	Nurock, Vanessa
Détermination du ticket modérateur en fonction de la valeur sociétale de la prestation ou du produit	Cleemput, Irina
Equality of opportunity	Roemer, John E.
Applied regression analysis and other multivariable methods	Kleinbaum, David G.
Discernement morale et discernement spirituel
The economics of health care	McGuire, Alistair
An introduction to randomized controlled clinical trials	Matthews, John N.S.
The SAGE handbook of health care ethics	Have, H. Ten, Meslin, Eric Mark

Belgische richtlijnen voor economische evaluaties en budget impact analyses / Irina Cleemput / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2012)  

Belgische richtlijnen voor economische evaluaties en budget impact analyses : tweede editie [printed text] / Irina Cleemput , Author ; Mattias Neyt , Author ; Stefaan Van de Sande , Author ; Nancy Thiry, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2012 . - VIII, 76 p. : ill. ; A4. - (KCE Reports A. Health Technology Assessment (HTA); 183A) . ISSN : D/2012/10273/52 : € 0,00 Studie n° 2011-44 HTA Pharma-Eco Evaluation Update Languages : English (eng) Dutch (nla) Descriptors: Classification QV 736 Drug industry. Economics of pharmacy. Advertising Indexation 2011-44 ; Economics, Pharmaceutical ; Guidelines as Topic ; R183 Abstract: Het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) en het RIZIV ontwikkelden in 2008 richtlijnen waaraan de aanvragen tot terugbetaling van bepaalde geneesmiddelen (klasse 1) moeten voldoen. Het KCE heeft deze nu herzien en aangevuld met richtlijnen voor het uitvoeren van een budgetimpact analyse. Al deze richtlijnen werden bovendien uitgebreid naar alle medische interventies ( naast de geneesmiddelen ook prothesen, implantaten, evenals alle andere medische prestaties).Dit moet zorgen voor meer transparantie en consistentie van de economische analyses en het RIZIV helpen om betere en meer gemotiveerde beslissingen te nemen. Contents note: SCIENTIFIC REPORT 8 -- 1 BACKGROUND 8 -- 2 OBJECTIVES 10 -- 3 METHODS10 -- 4 OVERVIEW OF THE BELGIAN GUIDELINES AND GENERAL REMARKS 12 -- 4.1 OVERVIEW OF THE BELGIAN GUIDELINES 12 -- 4.2 GENERAL REMARKS 13 -- 5 GUIDELINES FOR HEALTH ECONOMIC EVALUATIONS 15 -- 5.1 GUIDELINE 1: LITERATURE REVIEW 15 -- 5.2 GUIDELINE 2: PERSPECTIVE OF THE EVALUATION 17 -- 5.3 GUIDELINE 3: TARGET POPULATION 18 -- 5.4 GUIDELINE 4: COMPARATORS 19 -- 5.5 GUIDELINE 5: ANALYTIC TECHNIQUE 21 -- 5.5.1 Cost-effectiveness analysis 21 -- 5.5.2 Cost-utility analysis 22 -- 5.5.3 Cost-minimisation analysis 22 -- 5.5.4 Cost-benefit analysis 23 -- 5.6 GUIDELINE 6: STUDY DESIGN 23 -- 5.6.1 Trial-based economic evaluations 23 -- 5.6.2 Modelling 24 -- 5.7 GUIDELINE 7: CALCULATION OF COSTS 25 -- 5.7.1 Cost categories 25 -- 5.7.2 Measurement of resource use 26 -- 5.7.3 Valuation of resource use 26 -- 5.8 GUIDELINE 8: ESTIMATION AND VALUATION OF OUTCOMES 36 -- 5.8.1 Effectiveness evaluation in cost-effectiveness analysis 37 -- 5.8.2 Utility assessment in cost-utility analysis 37 -- 5.9 GUIDELINE 9: TIME HORIZON 39 -- 5.10 GUIDELINE 10: MODELLING 39 -- 5.10.1 Need for modelling 39 -- 5.10.2 Choice of the model design 40 -- 5.10.3 Precision of model structure and hypotheses 40 -- 5.10.4 Calibration, face validity and cross-validation of a model 41 -- 5.11 GUIDELINE 11: HANDLING UNCERTAINTY AND TESTING THE ROBUSTNESS OF THE RESULTS .. 42 -- 5.12 GUIDELINE 12: DISCOUNT RATE 43 -- 6 GUIDELINES FOR BUDGET IMPACT ANALYSES 44 -- 6.1 SIMILARITIES AND DIFFERENCES BETWEEN ECONOMIC EVALUATIONS AND BUDGET IMPACT -- ANALYSES 44 -- 6.2 GUIDELINE 13: PERSPECTIVE 45 -- 6.3 GUIDELINE 14: TARGET POPULATION 45 -- 6.4 GUIDELINE 15: COMPARATORS 46 -- 6.5 GUIDELINE 16: COSTS AND OUTCOMES 47 -- 6.6 GUIDELINE 17: TIME HORIZON 48 -- 6.7 GUIDELINE 18: MODELLING 48 -- 6.8 GUIDELINE 19: HANDLING UNCERTAINTY 49 -- 6.9 GUIDELINE 20: DISCOUNT RATE 49 -- 6.10 GUIDELINE 21: PRESENTING RESULTS 49 -- 7 DISCUSSION 50 -- 8 POLICY RECOMMENDATIONS 51 -- 9 REPORTING GUIDELINES 53 -- 9.1 EXECUTIVE SUMMARY 53 -- 9.2 INTRODUCTION 53 -- 9.3 OBJECTIVES 53 -- 9.4 LITERATURE REVIEW 53 -- 9.4.1 Clinical literature review 53 -- 9.4.2 Economic literature review 54 -- 9.5 BASIC ELEMENTS OF THE ECONOMIC EVALUATION 54 -- 9.5.1 Analytic technique 54 -- 9.5.2 Study design 54 -- 9.5.3 Methods used for valuation of costs 54 -- 9.5.4 Methods used for outcome assessment 54 -- 9.5.5 Method of analysis of the data 54 -- 9.5.6 Time horizon and discount rate54 -- 9.5.7 Sensitivity analysis 54 -- 9.6 RESEARCH METHODS 54 -- 9.6.1 Identification, measurement and valuation of costs 54 -- 9.6.2 Identification, measurement and valuation of health-related outcomes 55 -- 9.7 RESULTS 55 -- 9.7.1 Basic results 55 -- 9.7.2 Uncertainty analysis 55 -- 9.8 DISCUSSION 55 -- 9.9 CONCLUSION 55 -- 9.10 TRANSPARENCY OF FINANCIAL SUPPORT 55 -- 9.11 REFERENCES 56 -- 9.12 ADDENDA 56 -- 10 PRESENTATION OF A MODEL 56 -- 10.1 DATA 56 -- 10.2 RESULTS 56 -- 10.2.1 Reference case analysis 56 -- 10.2.2 Uncertainty analysis 56 -- 11 METHODOLOGICAL REFERENCES BY TOPIC 57 -- 11.1 COUNTRY-SPECIFIC GUIDELINES 57 -- 11.2 METHODS FOR ECONOMIC EVALUATIONS 57 -- 11.3 LITERATURE REVIEW 58 -- 11.4 STUDY DESIGN 58 -- 11.4.1 Trial-based economic evaluations 58 -- 11.4.2 Modelling 58 -- 11.5 CALCULATION OF COSTS 58 -- 11.5.1 Measurement of resource use 58 -- 11.5.2 Valuation of resource use 58 -- 11.6 HANDLING UNCERTAINTY 58 -- 11.6.1 Overview 58 -- 11.6.2 Confidence interval around the ICER 59 -- 11.7 INDIRECT COMPARISONS 59 -- 11.8 DISCOUNTING 59 -- 11.9 BUDGET IMPACT ANALYSES 59 -- APPENDICES 60 -- APPENDIX 1. CLASSIFICATION OF ECONOMIC STUDIES 60 -- APPENDIX 2. CHECKLIST FOR ASSESSING ECONOMIC EVALUATIONS 61 -- APPENDIX 3. DATA EXTRACTION SHEET FOR ECONOMIC EVALUATIONS 61 -- APPENDIX 4. TECHNICAL NOTES 62 -- APPENDIX 4.1. ASSESSMENT OF EXTERNAL VALIDITY 62 -- APPENDIX 4.2. OUTCOME VALUATION 63 -- APPENDIX 4.3. USE OF EXPERT PANELS 64 -- APPENDIX 4.4. HOSPITAL PER DIEM PRICES 64 -- APPENDIX 4.5. INDIRECT COMPARISONS 66 -- APPENDIX 5. THE COST-EFFECTIVENESS PLANE, COST-EFFECTIVENESS ACCEPTABILITY CURVE, AND EFFICIENCY FRONTIER 67 -- APPENDIX 6. LIST OF BELGIAN DATABASES FOR THE MEASUREMENT AND VALUATION OF RESOURCE USE 70 -- APPENDIX 7. FLEMISH EQ-5D INDEX VALUES 73 -- REFERENCES 74 Link for e-copy: https://doi.org/10.57598/R183A Format of e-copy: pdf (805 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3022

Copies(0)

Status
No copy

BMJ Best Practice / BMJ Journals (2022)  

BMJ Best Practice [printed text] . - BMJ Journals, 2022. Languages : English (eng) Descriptors: Classification W 26.55.I4 Information systems. Information storage and retrieval Indexation Database ; Diagnosis ; Evidence-Based Medicine ; Guidelines as Topic Contents note: OVERVIEW -- THEORY -- DIAGNOSIS -- MANAGEMENT -- FOLLOW UP -- RESOURCES -- Overview -- Summary -- Theory -- Epidemiology -- Aetiology -- Case history -- Diagnosis -- Recommendations -- History and exam -- Investigations -- Differentials -- Criteria -- Screening -- Management -- Recommendations -- Treatment algorithm -- Emerging -- Prevention -- Patient discussions -- Follow up -- Monitoring -- Complications -- Prognosis -- Resources -- Guidelines -- Images and videos -- References -- Patient leaflets Link for e-copy: https://ebpnet.be/nl/ebsources?searchTerm=&filter_publisher=39219 Format of e-copy: Page web Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=5040

Budget impact projecties voor geneesmiddelen / Irina Odnoletkova / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2024)  

Permalink

Budget impact projections for pharmaceuticals / Irina Odnoletkova / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2024)  

Permalink

Guidelines for pharmacoeconomic evaluations in Belgium / Irina Cleemput / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)  

Permalink

Improving access and use of psychotropic medicines / World Health Organization. Dept. of Mental Health and Substance Dependence. / Geneva [Switzerland] : World Health Organisation (WHO) (2005)  

Permalink

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses / David Moher in Lancet (The), 354(1999)9193 ([11/27/1999])  

Permalink

Mental health financing / Michelle Funk ; Benedetto Saraceno ; Vijay Ganju ; Martin Knapp ; David McDaid ; World Health Organization / Geneva [Switzerland] : World Health Organisation (WHO) (2003)

Permalink

Mental health information systems / World Health Organization. Dept. of Mental Health and Substance Dependence. / Geneva [Switzerland] : World Health Organisation (WHO) (2005)  

Permalink

Mental health legislation & human rights / Michelle Funk ; Benedetto Saraceno ; Soumitra Pathare ; Alberto Minoletti ; World Health Organization / Geneva [Switzerland] : World Health Organisation (WHO) (2003)

Permalink

Methodological guidelines / Ministry of Health of Brazil (2009)  

Permalink

Projections de l’impact budgétaire des produits pharmaceutiques / Irina Odnoletkova / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2024)  

Permalink